Gabriele Stefanzl
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.
Journal: Current allergy and asthma reports
Published: October 05, 2025
Soluble FcεRI is increased in advanced mastocytosis and acts as a negative regulator of mast cell expansion and activation.
Journal: The Journal of allergy and clinical immunology
Published: September 11, 2025
Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils.
Journal: Cells
Published: December 07, 2023
Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis.
Journal: Leukemia
Published: December 30, 2022
Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph+ Chronic Myeloid Leukemia.
Journal: Cells
Published: August 29, 2022
Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study.
Journal: American journal of cancer research
Published: June 29, 2022
N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
Journal: American journal of hematology
Published: June 20, 2022
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia.
Journal: American journal of hematology
Published: March 08, 2022
Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils.
Journal: The Journal of allergy and clinical immunology
Published: February 15, 2022
CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells.
Journal: Cancers
Published: December 31, 2021
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis.
Journal: Neoplasia (New York, N.Y.)
Published: June 25, 2021
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.
Journal: American journal of cancer research
Published: March 30, 2021
Last Updated: 09/26/2026